# US 2014/0154271 A1 · Methods of Treating Glucose Metabolism Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154271 A1
- Document ID: US20140154271A1
- Status: Published application
- Kind: A1
- Application number: 14/119,263
- Filed: 2012-05-31
- Published: 2014-06-05
- Earliest claimed: 2011-06-13
- Assignees: NGM Biopharmaceuticals, Inc.
- Inventors: Maria Deato; Hong Yang; Daniel David Kaplan
- Web page: https://patentgrep.com/patent/US20140154271A1

## CPC

- C07K 14/4701: {not used}
- C07K 14/47: from mammals
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.

## Claims

### Claim 1

A method of treating a subject comprising:
administering to said subject having a glucose metabolism disorder a therapeutically effective amount of a protein comprising at least 82% amino acid sequence identity to an amino acid sequence of human C15ORF61/2300009A05RIK, wherein said administering is effective treat a symptom of a glucose metabolism disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein said glucose metabolism disorder comprises hyperglycemia and wherein said administering reduces plasma glucose in said subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein said glucose metabolism disorder comprises hyperinsulinemia and wherein said administering reduces plasma insulin in said subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein said glucose metabolism disorder comprises glucose intolerance and wherein said administering increases glucose tolerance in said subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein said glucose metabolism disorder comprises diabetes mellitus.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is obese.

### Claim 7 (depends on 1)

The method of claim 1, wherein said glucose metabolism disorder is diet-induced.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject is human.

### Claim 9 (depends on 1)

The method of claim 1, wherein said administering is by parenteral injection.

### Claim 10 (depends on 9)

The method of claim 9, wherein said parenteral injection is subcutaneous.

### Claim 11

A pharmaceutical composition comprising:
a) a purified C15ORF61/2300009A05RIK polypeptide comprising an amino acid sequence having at least 82% amino acid sequence identity to an amino acid sequence of human C15ORF61/2300009A05RIK; and
b) a pharmaceutically acceptable excipient.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the excipient is an isotonic injection solution.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the composition is suitable for human administration.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the C15ORF61/2300009A05RIK polypeptide is present in a fusion protein comprising a human immunoglobulin Fc region fused to the carboxyl terminus of the C15ORF61/2300009A05RIK polypeptide.

### Claim 15 (depends on 11)

A sterile container comprising the composition of claim 11.

### Claim 16 (depends on 15)

The container of claim 15, wherein the container is a syringe.

### Claim 17 (depends on 15)

A kit comprising the sterile container of claim 15.